SULT1A2 is a cytosolic sulfotransferase that catalyzes the sulfate conjugation of phenolic compounds, catecholamines, and xenobiotics using 3'-phosphoadenosine 5'-phosphosulfate (PAPS) as the sulfonate donor 1. The enzyme exhibits a thermostable phenotype and functionally differs from its paralog SULT1A1 through structural variations, particularly at residue Tyr149, which influences substrate binding affinity and catalytic efficiency 2. SULT1A2 contains multiple naturally occurring allelic variants (*1, *2, *3) with distinct biochemical properties that show significant ethnic variation in frequency, with Asian populations predominantly carrying the *1 allele while African-American and Caucasian populations display higher frequencies of variant alleles 3. The gene exhibits strong linkage disequilibrium with SULT1A1*2, suggesting coordinated inheritance patterns 4. Clinically, SULT1A2 polymorphisms influence drug metabolism: carriers of *2 and *3 alleles demonstrate elevated plasma levels of tamoxifen metabolites, potentially affecting therapeutic efficacy in breast cancer treatment 5. Additionally, the rs1059491 variant has been nominally associated with reduced obesity and dyslipidemia risk in Chinese populations 6, and SULT1A2 variants contribute to sorafenib response prediction in hepatocellular carcinoma patients 7. These findings establish SULT1A2 as a pharmacogenetically important enzyme with significant inter-individual variability.